Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/03/2892199/0/en/Entera-Bio-Reports-Phase-1-Clinical-Data-of-First-in-Class-Oral-PTH-1-34-Peptide-Candidate-EB612-for-Patients-with-Hypoparathyroidism-at-ENDO-2024.html
https://www.globenewswire.com/news-release/2024/03/20/2849325/0/en/Entera-Bio-Announces-Robust-Pharmacokinetic-Data-for-First-in-Class-Oral-GLP-2-Peptide-Tablet-Treatment-for-Patients-with-Short-Bowel-Syndrome.html
https://www.globenewswire.com/news-release/2023/06/07/2683653/0/en/Entera-Bio-Adds-Sanofi-Commercial-Leader-Haya-Taitel-to-its-Board-of-Directors.html
https://endpts.com/amgen-and-entera-bio-call-off-oral-drug-delivery-partnership-after-four-years/
https://www.globenewswire.com/news-release/2023/03/31/2638997/0/en/Entera-Bio-Provides-2022-Corporate-Milestones-and-Financial-Results-for-the-Year-Ended-December-31-2022.html
https://www.globenewswire.com/news-release/2023/02/15/2608935/0/en/Entera-Bio-Announces-FDA-s-Acceptance-of-a-Type-D-Meeting-Review-to-Affirm-Design-of-the-Pivotal-Phase-3-Protocol-for-EB613-PTH-Mini-Tablets-as-the-First-Oral-Osteoanabolic-Treatme.html
https://www.globenewswire.com/news-release/2023/02/13/2606702/0/en/Entera-Bio-to-Participate-in-the-SVB-Securities-Global-Biopharma-Conference.html
https://www.globenewswire.com/news-release/2022/11/10/2553828/0/en/Entera-Bio-Provides-Corporate-Updates-and-Financial-Results-for-the-Third-Quarter-of-2022.html
https://www.globenewswire.com/news-release/2022/08/11/2496494/0/en/Entera-Bio-Provides-Business-Highlights-and-Financial-Results-for-the-Second-Quarter-2022.html
https://www.globenewswire.com/news-release/2021/08/23/2284989/0/en/Entera-Bio-to-Conduct-Annual-Shareholders-Meeting-on-October-4-2021.html